Onco-Innovations Ltd.

As of July 31, 2026, Onco-Innovations Ltd. carries a market capitalization of 44.40M, placing it among publicly traded companies globally. Its enterprise value stands at 44.57M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of July 31, 2026, Onco-Innovations Ltd. has 68.31M shares outstanding.

These figures are as of July 31, 2026. The price-to-sales ratio is 411.82, and the price-to-book ratio stands at 15.67.

These figures are as of July 31, 2026. The EV/Sales ratio of 490.43 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 44.57M versus a market cap of 44.40M, with the gap driven by net debt and cash on the balance sheet.

As of July 31, 2026, Onco-Innovations Ltd. maintains a current ratio of 1.89, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 9.94, indicating elevated leverage, while an interest coverage ratio of -6,198.65 demonstrates limited ability to service its debt obligations.

Over the twelve months ended July 31, 2026, Onco-Innovations Ltd. posted a negative return on equity (ROE) of -592.62, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -378.59, reflecting losses generated across the asset base.

As of the close on October 22, 2026, Onco-Innovations Ltd.'s stock has declined approximately 80.00% over the past 52 weeks. The 50-day moving average sits at 0.44, while the 200-day moving average is 0.74.

Over the twelve months ended July 31, 2026, Onco-Innovations Ltd. generated 90,878.00 in revenue and converted that into -11.47M in net income, yielding earnings per share of -0.20. EBITDA reached -10.43M, while operating income came in at -10.43M.

As of July 31, 2026, Onco-Innovations Ltd. holds 114,385.00 in cash and equivalents against 281,682.00 in total debt, resulting in a net debt position of 167,297.00. Total book value stands at 2.83M, with working capital of 1.51M providing operational flexibility.

Onco-Innovations Ltd. produced -4.08M in operating cash flow over the twelve months ended July 31, 2026.

These figures cover the twelve months ended July 31, 2026. The operating margin of -11,472.67 and net profit margin of -12,625.19 provide insight into operational efficiency.

These figures cover the twelve months ended July 31, 2026. Free cash flow yield is negative at -10.89: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -7.31, meaning Onco-Innovations Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of July 31, 2026, Onco-Innovations Ltd. has an Altman Z-Score of 1.81, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.